Cleared Traditional

REVISED LABELING FOR OPIATES (K874485) - FDA 510(k) Clearance

Class II Toxicology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K874485 · Abbott Laboratories · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1987
Decision
24d
Days
Class 2
Risk

K874485 is an FDA 510(k) clearance for the REVISED LABELING FOR OPIATES. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on November 23, 1987 after a review of 24 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3650 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Abbott Laboratories devices

Submission Details

510(k) Number K874485 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 30, 1987
Decision Date November 23, 1987
Days to Decision 24 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
63d faster than avg
Panel avg: 87d · This submission: 24d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 88
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K874485.
EMIT HVA OPIATE ASSAY
K881941 · Syva Co. · Aug 1988
COAT-A-COUNT OPIATES SCREEN TKOS1, TKOS5
K874808 · Diagnostic Products Corp. · Feb 1988
REVISED LABELING FOR ADX OPIATES
K880010 · Abbott Laboratories · Feb 1988
REVISED LABELING FOR MORPHINE TEST KIT
K874268 · Roche Diagnostic Systems, Inc. · Nov 1987
REVISED LABELING FOR SYVA OPIATE ASSAYS
K873898 · Syva Co. · Oct 1987
LABELING CHANGE COAT-A-COUNT MORPHINE IN URINE
K873757 · Diagnostic Products Corp. · Oct 1987